SCHEMBL21189363

SCHEMBL21189363

COC(=O)NC1CCNc2c(C(=O)Nc3ccc(F)c(Cl)c3)cccc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.46
NPC1 O15118 4/20 0.46
RAB9A P51151 4/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
HPGD P15428 1/20 0.46
FADS1 O60427 1/20 0.46
KMT2A Q03164 3/20 0.43
ALDH1A1 P00352 2/20 0.43
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
HTT P42858 1/20 0.42
APOB P04114 1/20 0.42
MTTP P55157 1/20 0.42
HDAC3 O15379 1/20 0.40
EGFR P00533 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC10 Q969S8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19973579 0.90 FADS1 (0.48) MAPTNPC1RAB9ASMN1; SMN2HPGD
SCHEMBL21189278 0.81 FADS1 (0.46) MAPTNPC1RAB9ASMN1; SMN2HPGD
SCHEMBL21189261 0.81 FADS1 (0.45) MAPTNPC1RAB9ASMN1; SMN2HPGD
SCHEMBL19973434 0.81 TP53 (0.46) MAPTNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL26715030 0.79 FADS1 (0.47) MAPTNPC1RAB9ASMN1; SMN2HPGD
SCHEMBL21189438 0.76 NPC1 (0.44) MAPTNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL26597481 0.76 FADS1 (0.47) MAPTNPC1RAB9ASMN1; SMN2HPGD
SCHEMBL29044051 0.75 FADS1 (0.47) MAPTNPC1RAB9ASMN1; SMN2HPGD
SCHEMBL26705675 0.74 KMT2A (0.46) MAPTNPC1RAB9ASMN1; SMN2HPGD
SCHEMBL23496516 0.74 KMT2A (0.44) MAPTNPC1RAB9ASMN1; SMN2FADS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2021-05-11 US disclosed
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2019-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME CBX8, HAVCR2, HCCS MAPT 3165/4885NPC1 983/4885RAB9A 1393/4885
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same CBX8, HAVCR2, HCCS MAPT 3165/4885NPC1 983/4885RAB9A 1393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.